See the DrugPatentWatch profile for Lucentis
Lucentis biosimilar development is underway, with multiple companies working on versions of the drug. These biosimilars aim to offer a more affordable alternative to the originator biologic.
What is Lucentis and What Does It Treat?
Lucentis, also known by its generic name ranibizumab, is an antibody fragment used to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other serious eye conditions. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes the growth of abnormal blood vessels in the eye, which can lead to vision loss [1].
Who is Developing Lucentis Biosimilars?
Several pharmaceutical companies are engaged in the development and potential commercialization of Lucentis biosimilars. These include Samsung Bioepis, which has developed Byooviz, and Celltrion, which has developed Herzuma [2][3]. Viatris has also partnered with Biocad to develop biosimilars for Lucentis and Eylea [4].
When Can Biosimilars Enter the Market?
The market entry for Lucentis biosimilars is often tied to patent expiry and regulatory approvals. In the United States, Byooviz, developed by Samsung Bioepis and marketed by Biogen, received FDA approval in April 2022 [2]. Herzuma, developed by Celltrion, also received FDA approval in September 2022 [3]. Patent challenges and litigation can influence the exact launch dates of biosimilars. Information on patent expiry for specific drugs can be found on DrugPatentWatch.com [5].
What is the Difference Between Lucentis and its Biosimilars?
Biosimilars are highly similar to their reference biologic products, with no clinically meaningful differences in terms of safety, purity, and potency. The differences are typically minor and do not impact the drug's efficacy or safety profile. Byooviz, for instance, is a biosimilar to Lucentis and is indicated for the same diseases [2].
How Do Lucentis Biosimilars Affect Drug Pricing?
The introduction of biosimilars is expected to increase competition and drive down the cost of treatment for conditions like AMD. This can lead to significant savings for healthcare systems and patients.
What is the Regulatory Pathway for Biosimilars?
In the United States, biosimilars are approved by the Food and Drug Administration (FDA) through a rigorous review process that demonstrates their high degree of similarity to the reference product. This involves analytical studies, animal studies, and in some cases, clinical studies to confirm no meaningful differences in safety and efficacy [6].
What are the Clinical Data and Patient Concerns for Biosimilars?
Clinical trials for biosimilars, such as those conducted for Byooviz and Herzuma, compare their efficacy and safety profiles directly against the reference product, Lucentis. These studies generally confirm that biosimilars have similar outcomes in terms of visual acuity and safety [2][3]. Patient concerns often revolve around the interchangeability of biosimilars with the reference product, though regulatory approvals address this through scientific evidence.
What are the Risks Associated with Biosimilar Adoption?
While biosimilars offer cost benefits, potential risks can include physician and patient hesitancy due to unfamiliarity, and complexities in formulary management and reimbursement policies. However, the FDA's approval process is designed to ensure that biosimilars are as safe and effective as their reference products [6].
Sources:
[1] https://www.gene.com/media/press-releases/14988/gene-and-genentech-announce-fda-approval-of-lucentis-r
[2] https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-treatments-eye-conditions-amd-and-diabetic-macular-edema
[3] https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-additional-biosimilar-treatments-eye-conditions-amd-and-diabetic-macular-edema
[4] https://www.fiercepharma.com/manufacturing/viatris-taps-biocad-co-develop-biosimilar-versions-regenerons-eylea-and-roche-s-lucentis
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/drugs/biosimilars/patient-information-about-biosimilars